Track how companies discuss tariffs and trade policies in their earnings calls, and understand their impact across different industries and regions.
we have not seen any pull-ins to date due to tariffs and our diversified manufacturing footprint remains a competitive advantage.
We expect an immaterial cost impact from tariffs in 2025 based on what we know today due to our significant U.S. presence and our geographically diverse supply chain.
Adjusted EBITDA margin of 25.7% came in ahead of expectations due to higher revenue and operating leverage as well as benefiting from the timing of tariffs, which will now impact us more in the second half of the year.
Gross margin for the quarter was 58.3%, and adjusted operating margin was 29.1%, reflecting the impact of regional sales mix and margin dilution from tariff surcharges.
Our exposure to tariffs is negligible across our operations. And importantly, Canadian oil and gas delivered to the U.S. via our systems has not attracted tariffs.
The macro environment has been volatile and uncertain with tariff policies changing frequently.
deployment environment was modestly impacted, particularly at the beginning of the quarter...as the markets adjusted for the impact of new tariff policies.
we do not currently expect a 15% tariff on non-generic pharmaceutical products to have a material impact on our financial results in 2025.
these results do reflect our estimate of tariff-related LIFO inventory valuation headwinds.
my initial reaction is what we're going to do is see trade flows maybe change, but ultimately, the world is round and there's still a level of demand that has to be met